| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| Company: Leuko |
| Recipient: An Immediate Family Member |
| Company: MAJ3 Capital |
| Recipient: You |
|
| Honoraria |
| Company: Novartis |
| Recipient: You |
| Company: Eisai |
| Recipient: You |
| Company: Celgene |
| Recipient: You |
| Company: Pfizer |
| Recipient: You |
| Company: Roche |
| Recipient: You |
| Company: Samsung |
| Recipient: You |
| Company: Lilly |
| Recipient: You |
| Company: Merck Sharp & Dohme |
| Recipient: You |
| Company: Daiichi Sankyo |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
| Company: Gilead Sciences |
| Recipient: You |
| Company: Steamline Therapeutics |
| Recipient: You |
| Company: Zuellig Pharma |
| Recipient: You |
|
| Consulting or Advisory Role |
| Company: Celgene |
| Recipient: You |
| Company: Cellestia Biotech |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
| Company: Roche |
| Recipient: You |
| Company: Seattle Genetics |
| Recipient: You |
| Company: Daiichi Sankyo |
| Recipient: You |
| Company: ERYTECH Pharma |
| Recipient: You |
| Company: Polyphor |
| Recipient: You |
| Company: Athenex |
| Recipient: You |
| Company: Lilly |
| Recipient: You |
| Company: SERVIER |
| Recipient: You |
| Company: Merck Sharp & Dohme |
| Recipient: You |
| Company: GlaxoSmithKline |
| Recipient: You |
| Company: Leuko |
| Recipient: You |
| Company: Clovis Oncology |
| Recipient: You |
| Company: Bioasis |
| Recipient: You |
| Company: Boehringer Ingelheim |
| Recipient: You |
| Company: Ellipses Pharma |
| Recipient: You |
| Company: HiberCell |
| Recipient: You |
| Company: Bioinvent |
| Recipient: You |
| Company: GEMoaB |
| Recipient: You |
| Company: Gilead Sciences |
| Recipient: You |
| Company: Menarini |
| Recipient: You |
| Company: Zymeworks |
| Recipient: You |
| Company: Reveal Genomics |
| Recipient: You |
| Company: ExpreS2ion Biotechnologies ApS |
| Recipient: You |
| Company: Jazz Pharmaceuticals |
| Recipient: You |
| Company: Abbvie |
| Recipient: You |
| Company: Bridgebio |
| Recipient: You |
| Company: BioNTech SE |
| Recipient: You |
| Company: Biocon |
| Recipient: You |
| Company: Circle Pharma |
| Recipient: You |
| Company: Delcath Systems |
| Recipient: You |
| Company: Hexagon Bio |
| Recipient: You |
| Company: Bliss Biopharmaceutical |
| Recipient: You |
| Company: Relay Therapeutics |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: ARIAD |
| Recipient: Your Institution |
| Company: Astrazeneca |
| Recipient: Your Institution |
| Company: Baxalta GMBH/ Servier Affaires |
| Recipient: Your Institution |
| Company: Bayer |
| Recipient: Your Institution |
| Company: Eisai Farmaceutica |
| Recipient: Your Institution |
| Company: Guardanth health |
| Recipient: Your Institution |
| Company: Merck Sharp & Dohme |
| Recipient: Your Institution |
| Company: Pfizer |
| Recipient: Your Institution |
| Company: Puma CO |
| Recipient: Your Institution |
| Company: Queen Mary university of London |
| Recipient: Your Institution |
| Company: Roche |
| Recipient: Your Institution |
| Company: Piqur |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| Please describe: Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A. |
| Recipient: You |
| Please describe: Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1 |
| Recipient: You |
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| Company: Roche |
| Recipient: You |
| Company: Pfizer |
| Recipient: You |
| Company: Eisai |
| Recipient: You |
| Company: Novartis |
| Recipient: You |
| Company: Daiichi Sankyo |
| Recipient: You |
| Company: Gilead |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
| Company: Merck Sharp&Dhome |
| Recipient: You |
| Company: Steamline Therapeutics |
| Recipient: You |
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| not answered |
|
|
| (OPTIONAL) Open Payments Link |
| not answered |
|
|